Celldex Therapeutics, Inc.

CLDX

$39.37

-0.28%

N/A-$0.11

Healthcare

Biotechnology

NASDAQ

Active Trading

Celldex Therapeutics, Inc. is a biopharmaceutical company dedicated to developing antibody-based treatments, specifically monoclonal and bispecific antibodies, for a range of diseases. ...

Key Metrics of CLDX

Snapshot

Latest / TTM · 6 periods

Market Cap

$2.62B

ROCE

-45.2%

EV / EBITDA

-8.67x

+8.8% YoY

FCF Yield

-9.2%

+2.6% YoY

Cash Conversion Cycle

665.6d

Current Ratio

11.82

Quick take

TTM —

Positive CCC

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$1.66B	$2.09B	$1.92B	$1.63B	$1.81B	$2.62B
Enterprise ValueCompany value including debt and cash adjustments.	$1.62B	$2.06B	$1.89B	$1.60B	$1.78B	$2.58B
EV / SalesHow many dollars investors pay per dollar of sales.	348.40x	875.86x	274.48x	228.31x	1186.40x	23009.55x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-24.52x	-19.81x	-13.59x	-10.36x	-6.97x	-8.67x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	0.55	0.24	0.23	0.16	0.10	0.14

Returns + ROCE gauge

ROCE latest

-45.2%

Prev year -54.0%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-16.8%	-34.4%	-33.0%	-21.1%	-49.1%	-52.4%
ROAProfit generated from total assets.	-15.9%	-31.8%	-30.4%	-19.9%	-44.4%	-38.4%
ROICReturn generated on invested operating capital.	-16.1%	-32.1%	-32.7%	-21.2%	-49.9%	-42.6%
ROCEOperating return on long-term capital used.	-16.6%	-34.5%	-35.6%	-25.9%	-54.0%	-45.2%
Earnings YieldEarnings as a percentage of market value.	-4.3%	-5.4%	-7.4%	-9.7%	-14.3%	-9.8%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-62.16M	$-105.56M	$-109.11M	$-159.70M	$-213.66M	$-241.82M
FCFECash flow available to equity holders after debt flows.	$-62.16M	$-105.56M	$-109.11M	$-159.70M	$-213.66M	$-241.82M
FCF YieldFree cash flow divided by market capitalization.	-3.8%	-5.1%	-5.7%	-9.8%	-11.8%	-9.2%
Income QualityHow well accounting earnings are backed by cash flow.	0.86	0.92	0.76	1.00	0.82	0.78
Capex / OCFShare of operating cash flow spent on capital expenditures.	-2.1%	-1.8%	-1.7%	-1.2%	-1.3%	-2.7%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	13.5d	53.7d	240.1d	36.4d	490.3d	749.6d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	8.4d	14.8d	10.8d	7.3d	0.0d	84.0d
Operating CycleTime from buying inventory to collecting receivables.	13.5d	53.7d	240.1d	36.4d	490.3d	749.6d
Cash Conversion CycleNet days cash is tied in operations.	5.1d	38.9d	229.3d	29.1d	490.3d	665.6d

Snapshot

Latest / TTM: —

Market Cap

$2.62B

ROE

-52.4%

FCF Yield

-9.2%

Current Ratio

11.82

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer